6505--Anti CD20 Antibodies (VA-24-00025874)

The Department of Veterans Affairs National Acquisition Center is seeking offers for anti-CD20 antibodies to be distributed through its Pharmaceutical Prime Vendor program. The solicitation requests pricing for ocrelizumab, ublituximab-XIIY, and ofatumumab for a one-year base period and four one-year options. Offerors must provide pricing for all five years for one of the line items to be considered for award. The awarded product will be the preferred agent listed on the VA National Formulary for anti-CD20 antibody indications and required for new patient starts unless clinically contraindicated. Offers are due no later than February 19, 2024 at 2:30PM Central Time.

There is no set-aside designated for this procurement. The solicitation falls under NAICS 325412 Pharmaceutical Preparation Manufacturing and PSC 6515 Medical Supplies. No current contractors or incumbents are identified. The awarded product will be the sole anti-CD20 antibody listed on the VA National Formulary to treat certain medical conditions for veterans. The period of performance covers one base year and four option years. Product distribution will occur nationwide through the VA Pharmaceutical Prime Vendor program.